Biologics Safety Testing Market
Report Code
BT 3334
Published in
May, 2026, By MarketsandMarkets™
Biologics Safety Testing Market by Product (Kits, Reagents, Instruments), Services, Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden), Product & Services by Application (Vaccines, mAbs, CGT), End User, Competition, Region - Global Forecast to 2031
USD 9.66 BN
MARKET SIZE, 2031
CAGR 11.6%
(2026-2031)
270
REPORT PAGES
260
MARKET TABLES
BIOLOGICS SAFETY TESTING MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global biologics safety testing market is projected to grow from USD 5.57 billion in 2026 to USD 9.66 billion by 2031, at a CAGR of 11.6% during the forecast period. The market was valued at USD 4.97 billion in 2025. Biologics safety testing comprises analytical products and services used to detect microbial contamination, endotoxins, mycoplasma, viruses, and process-related impurities, ensuring the safety, quality, and regulatory compliance of biologic products. The market includes assays, kits and reagents, instruments, and specialized testing services that support biologics development, manufacturing, and batch release across monoclonal antibodies, vaccines, cell and gene therapies, blood products, and other biologics.
KEY TAKEAWAYS
-
BY REGIONNorth America accounted for the largest market share, by region, in 2025: 43%.
-
BY OFFERINGBy offering, in 2025, the product segment had the largest share of 41.9%.
-
BY END USERPharmaceutical & biotechnology companies dominated the biologics safety testing products market in 2025 with a share of 56.0%.
-
COMPETITIVE LANDSCAPE - Key PlayersThermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Charles River Laboratories (US) were identified as some of the star players in the global biologics safety testing market, given their strong market share and product and service footprint.
-
COMPETITIVE LANDSCAPE - StartupsClean Biologics (France), PathoQuest (France), ARL Bio Pharma, Inc.(US), have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The global biologics safety testing market is expanding steadily, driven by the growing development of biologics, increasing regulatory focus on product safety, and rising demand for advanced testing solutions across development and manufacturing.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The biologics safety testing market is advancing steadily, driven by innovations in rapid microbiological methods, analytical technologies, automation, and evolving regulatory standards aligned with increasingly complex biologics development. The growing global demand for monoclonal antibodies, vaccines, biosimilars, and advanced therapies is accelerating the need for sensitive, reliable safety testing solutions. Expanding use of advanced assays, automated platforms, and specialized testing services is supporting more efficient detection of microbial contamination, endotoxins, mycoplasma, viruses, and process-related impurities. Scalable and validated testing technologies are gaining wider adoption, improving quality control, supporting regulatory compliance, and aligning with evolving manufacturing and quality expectations across major biopharmaceutical markets.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Rising Biologics and Biosimilars Pipeline
-
Stringent and Evolving Regulatory Requirements
RESTRAINTS
Impact
Level
Level
-
High Cost of Advanced Testing Equipment and Limited Specialized Expertise
-
Regulatory Divergence Across Regions
OPPORTUNITIES
Impact
Level
Level
-
Growing focus on next-generation therapeutics
-
Shift Toward Animal-Free Testing Approaches
CHALLENGES
Impact
Level
Level
-
Assay Standardization Gap
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising Biologics and Biosimilars Pipeline
The expanding biologics and biosimilars pipeline is driving demand for safety testing, as these products require rigorous validation at each development stage. Increasing approvals and complex modalities are accelerating the adoption of advanced assays to ensure quality, compliance, and faster commercialization timelines.
Restraint: High Cost of Advanced Testing Equipment and Limited Specialized Expertise
High costs of advanced biologics safety testing equipment and limited skilled expertise hinder market growth. Technologies such as rapid microbial detection and molecular assays require significant investment and technical capabilities, thereby restricting adoption among smaller biotech firms and emerging players, especially in developing regions.
Opportunity: Growing focus on next-generation therapeutics
The shift toward next-generation therapeutics, including cell and gene therapies, creates strong opportunities for biologics safety testing. These complex products require highly sensitive methods, driving innovation and increasing demand for specialized testing solutions to ensure safety, efficacy, and regulatory compliance globally.
Challenge: Assay Standardization Gap
Lack of assay standardization across biologics safety testing creates major challenges. Differences in protocols, validation requirements, and regulatory expectations lead to inconsistencies, complicating global development and approvals, while increasing costs, timelines, and operational complexity for manufacturers operating across multiple regions and product types.
BIOLOGICS SAFETY TESTING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Utilizes endotoxin detection kits, rapid sterility testing, and mycoplasma detection solutions to ensure the safety of biologics, including cell and gene therapies, across raw materials, in-process samples, and final products | Enables highly sensitive detection of contaminants such as endotoxins and mycoplasma, reducing batch failure risks, improving product quality, and supporting regulatory compliance through faster and more reliable safety testing workflows |
 |
Provides comprehensive biologics safety testing, including endotoxin (LAL-based) assays, mycoplasma detection, sterility, and viral safety testing across raw materials, in-process samples, and final biologic products, supporting cell and gene therapy manufacturing and regulatory submissions | Enables rapid, highly sensitive contamination detection with reduced turnaround times, improving product release efficiency, ensuring global regulatory compliance, and minimizing the risk of batch failure through robust, end-to-end safety testing strategies. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global biologics safety testing market is a highly interconnected ecosystem in which biopharmaceutical companies, biotechnology firms, and research institutions collaborate to ensure the safety and quality of complex biologics. Testing service providers and technology companies offer advanced solutions for endotoxin detection, sterility testing, mycoplasma screening, and viral safety. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) support testing across development and manufacturing stages. Regulatory authorities and healthcare systems across regions such as North America and Europe establish stringent guidelines, driving compliance and ensuring safe commercialization of biologics.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Global Biologics Safety Testing Market, by Offerings
In 2025, services dominated the biologics safety testing market due to increasing outsourcing to CROs and CDMOs, rising complexity of biologics, and the need for specialized expertise, driving higher adoption of end-to-end testing solutions across development and manufacturing stages.
Global Biologics Safety Testing Market, by Product
Assays, kits, and reagents held a significant share in 2025, driven by their widespread use in routine safety testing, including endotoxin, mycoplasma, and sterility testing, and by their ease of use, rapid results, and compatibility with standardized laboratory workflows.
Global Biologics Safety Testing Market, by Test Type
Residual host cell protein and DNA detection tests accounted for a major share in 2025, owing to stringent regulatory requirements for impurity testing and their critical role in ensuring product purity and safety in biologics manufacturing.
Global Biologics Saftey Testing Product Market, by Application
Monoclonal antibodies and therapeutic proteins dominated in 2025 due to their large pipeline, increasing approvals, and extensive safety testing requirements across all stages of development and commercial production.
Global Biologics Safety Testing Service Market, by Applications
Vaccine safety testing held a highest share in 2025, supported by ongoing global immunization programs, increased vaccine development, and stringent regulatory requirements for batch release and quality assurance.
GlobalBiologics Safety Testing Product Market, by Product End Users
In 2025, pharmaceutical & biotechnology companies accounted for the largest share among product end users, driven by high biologics production, in-house testing needs, and continuous demand for quality control and regulatory compliance.
Global Biologics Safety Testing Service Market, by Service End Users
Pharmaceutical & biotechnology companies also led in service end users in 2025, as they increasingly outsource complex safety testing to specialized providers to reduce costs, improve efficiency, and accelerate time-to-market.
REGION
Asia Pacific to be fastest-growing region in market during forecast period
During the forecast period, the Asia Pacific is expected to emerge as a fast-growing region in the global biologics safety testing market, driven by expanding biopharmaceutical manufacturing, increasing investments in biotechnology, and improving regulatory frameworks. Rising adoption of biologics, including biosimilars and vaccines, along with growing clinical trial activity, is boosting demand for safety testing. Additionally, the presence of cost-effective CROs and CDMOs, coupled with increasing outsourcing by global companies and advancements in testing capabilities, is further accelerating regional market growth.
BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX
In the global biologics safety testing market, Thermo Fisher Scientific is the star player, driven by its diverse portfolio of testing instruments, assay kits, and integrated services spanning endotoxin, sterility, and microbial detection. The company continues to lead through technological innovation, broad global reach, and strong partnerships with biopharma companies and CDMOs. Samsung Biologics is an emerging leader, with its expanding biologics manufacturing capabilities and integrated quality and safety testing services. Its focus on end-to-end bioprocessing support, advanced analytics, and strategic collaborations positions it strongly to capture growing demand for outsourced biologics safety testing.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Charles River Laboratories (US)
- Laboratory Corporation of America Holdings (US)
- Merck KGaA (Germany)
- Lonza (Switzerland)
- Fujifilm Corporation (Japan)
- BIOMERIEUX(France)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 4.97 Billion |
| Market Forecast in 2031 (Value) | USD 9.66 Billion |
| Growth Rate | CAGR of 11.6% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: BIOLOGICS SAFETY TESTING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Evaluate competitive positioning of key players in the biologics safety testing market | Analyzed portfolios of leading biologics safety testing providers across sterility testing, endotoxin testing, mycoplasma testing, virus safety testing, bioburden testing, and residual impurity testing; benchmarked players by service breadth, product depth, technology capabilities, geographic reach, and end-user focus | Supports strategic decision-making by identifying competitive white spaces, capability gaps, partnership targets, and differentiation opportunities |
| Assess high-growth testing segments and technology opportunities | Evaluated demand across major test categories, rapid microbiology methods, PCR/qPCR, NGS-based viral safety, recombinant endotoxin reagents, and automation-linked QC workflows | Helps prioritize the most attractive growth pockets, investment themes, and innovation areas in the biologics safety testing market |
RECENT DEVELOPMENTS
- December 2025 : Thermo Fisher Scientific Inc. expanded its Bioprocess Design Centers in Asia to strengthen support for biologics, vaccines, and cell and gene therapy development and manufacturing.
- January 2026 : Charles River Laboratories, Inc. acquired PathoQuest SAS to strengthen its biologics testing business with rapid, in vitro NGS-based viral safety, biopharmaceutical characterization, and product release testing capabilities.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
46
2
EXECUTIVE SUMMARY
51
3
PREMIUM INSIGHTS
57
4
MARKET OVERVIEW
Biologics market thrives on advanced therapies, regulatory shifts, and strategic cross-sector opportunities.
60
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
RISING BIOLOGICS AND BIOSIMILARS PIPELINE
4.2.1.2
STRINGENT AND EVOLVING REGULATORY REQUIREMENTS
4.2.1.3
GROWTH OF ADVANCED MODALITIES LIKE CELL & GENE THERAPIES AND MRNA PRODUCTS
4.2.1.4
RISING DEMAND FOR OUTSOURCED DEVELOPMENT/MANUFACTURING AND TESTING
4.2.2
RESTRAINTS
4.2.2.1
HIGH COST OF ADVANCED TESTING EQUIPMENT AND LIMITED SPECIALIZED EXPERTISE
4.2.2.2
REGULATORY DIVERGENCE ACROSS REGIONS
4.2.3
OPPORTUNITIES
4.2.3.1
GROWING FOCUS ON NEXT-GENERATION THERAPEUTICS
4.2.3.2
SHIFT TOWARD ANIMAL-FREE TESTING APPROACHES
4.2.4
CHALLENGES
4.2.4.1
ASSAY STANDARDIZATION GAP
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Navigate competitive pressures and pricing shifts to capitalize on biologics safety testing market growth.
67
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
BARGAINING POWER OF SUPPLIERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL BIOLOGICS SAFETY TESTING MARKET
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025
5.5.2
INDICATIVE SELLING PRICE, BY REGION, 2025
5.6
KEY CONFERENCES & EVENTS
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8
INVESTMENT/FUNDING ACTIVITY
5.9
IMPACT OF US TARIFFS—BIOLOGICS SAFETY TESTING MARKET
5.9.1
INTRODUCTION
5.9.2
KEY TARIFF RATES
5.9.3
PRICE IMPACT ANALYSIS
5.9.4
IMPACT ON COUNTRIES/REGIONS
5.9.4.1
NORTH AMERICA
5.9.4.2
EUROPE
5.9.4.3
ASIA PACIFIC
5.9.5
IMPACT ON END-USE INDUSTRIES
5.9.5.1
PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
5.9.5.2
CROS & CDMOS
5.9.5.3
ACADEMIC & RESEARCH INSTITUTES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI and advanced tech revolutionize biologics safety testing, driving innovation and market readiness.
85
6.1
KEY TECHNOLOGIES
6.1.1
POLYMERASE CHAIN REACTION (PCR)
6.1.2
NEXT-GENERATION SEQUENCING (NGS)
6.2
ADJACENT TECHNOLOGIES
6.2.1
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
6.3
COMPLEMENTARY TECHNOLOGIES
6.3.1
LAB-ON-A-CHIP (LOC) SYSTEMS
6.3.2
HIGH-CONTENT SCREENING (HCS)
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.5
PATENT ANALYSIS
6.5.1
TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015–2025
6.6
FUTURE APPLICATIONS
6.7
IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET
6.7.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Navigate complex global regulations and sustainability standards to enhance compliance and eco-innovation.
93
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
REGULATORY FRAMEWORK
7.1.3
INDUSTRY STANDARDS
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock buyer insights to navigate stakeholder influence and overcome adoption barriers effectively.
102
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
KEY BUYING CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5
MARKET PROFITABILITY
9
BIOLOGICS SAFETY TESTING MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 138 Data Tables
107
9.1
INTRODUCTION
9.2
SERVICES
9.2.1
VIRUS SAFETY TESTING SERVICES
9.2.1.1
RISING FOCUS ON DEVELOPMENT OF ADVANCED THERAPIES TO DRIVE GROWTH
9.2.2
STERILITY TESTING SERVICES
9.2.2.1
NEED FOR STERILITY TESTING AT EACH STAGE OF DRUG DEVELOPMENT TO PROPEL GROWTH
9.2.3
MYCOPLASMA TESTING SERVICES
9.2.3.1
INCREASING FOCUS ON DEVELOPMENT OF BIOLOGICS AND BIOSIMILARS TO PROMOTE GROWTH
9.2.4
ENDOTOXIN TESTING SERVICES
9.2.4.1
STRINGENT REGULATORY REQUIREMENTS TO DRIVE MARKET
9.2.5
BIOBURDEN TESTING SERVICES
9.2.5.1
RISING ADOPTION OF ADVANCED TESTING SOLUTIONS FOR CONTAMINATION RISK MITIGATION TO PROPEL THE GROWTH
9.2.6
OTHER BST SERVICES
9.3
PRODUCTS
9.3.1
ASSAYS, KITS, AND REAGENTS
9.3.1.1
DETECTION KITS
9.3.1.1.1
EXPANDING ADVANCED BIOLOGICS PIPELINES AND FASTER QC WORKFLOWS ARE LIFTING DEMAND FOR HIGH-SENSITIVITY DETECTION KITS
9.3.1.2
ENDOTOXIN TESTING REAGENTS
9.3.1.2.1
REGULATORY ACCEPTANCE OF RECOMBINANT METHODS AND SHIFT TO SIMPLER, ANIMAL-FREE QC WORKFLOWS ARE ACCELERATING DEMAND FOR ENDOTOXIN TESTING REAGENTS
9.3.1.3
STERILITY TESTING MEDIA & KITS
9.3.1.3.1
RAPID RELEASE NEEDS AND SHIFT TOWARD STANDARDIZED ASEPTIC QC STRENGTHEN DEMAND FOR STERILITY TESTING MEDIA AND KITS
9.3.1.4
BIOBURDEN ENUMERATION
9.3.1.4.1
STRICTER CONTAMINATION CONTROL EXPECTATIONS AND FASTER MICROBIOLOGY WORKFLOWS DRIVE DEMAND FOR BIOBURDEN ENUMERATION SOLUTIONS
9.3.1.5
OTHER BST ASSAYS, KITS, AND REAGENTS
9.3.2
INSTRUMENTS
9.3.2.1
DETECTION & IMAGING SYSTEMS
9.3.2.1.1
RAPID MOLECULAR TESTING, AUTOMATED MICROBIOLOGY, AND STANDARDIZED QC WORKFLOWS ARE INCREASING THE DEMAND
9.3.2.2
SEQUENCING INSTRUMENTS
9.3.2.2.1
WIDER ADOPTION OF NGS-BASED VIRAL SAFETY WORKFLOWS AND SMALLER, MORE ACCESSIBLE PLATFORMS SUPPORT DEMAND
9.3.2.3
AUTOMATED STERILITY TESTING SYSTEMS
9.3.2.3.1
SHORTER RELEASE TIMELINES AND WIDER ADOPTION OF RAPID MICROBIOLOGY TO DRIVE GROWTH
9.3.2.4
OTHER BST INSTRUMENTS
10
BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 50 Data Tables
172
10.1
INTRODUCTION
10.2
VIRUS SAFETY TESTS
10.2.1
GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
10.3
STERILITY TESTS
10.3.1
MANDATORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO PROMOTE SEGMENT GROWTH
10.4
ENDOTOXIN TESTS
10.4.1
GROWING R&D ACTIVITIES FOR DEVELOPMENT OF BIOLOGICS TO PROMOTE THE GROWTH OF THE SEGMENT
10.5
MYCOPLASMA TESTS
10.5.1
RISING CONCERN FOR CELL CULTURE CONTAMINATION TO DRIVE THE SEGMENT GROWTH
10.6
BIOBURDEN TESTS
10.6.1
GROWING CONCERNS FOR DRUG SAFETY STANDARDS HAVE INCREASED THE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING IN THE BIOLOGICS INDUSTRY
10.7
RESIDUAL HCP & DNA DETECTION TESTS
10.7.1
STRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO CONTRIBUTE TO THE SEGMENT GROWTH
10.8
OTHER TESTS
11
BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
197
11.1
INTRODUCTION
11.2
MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS
11.2.1
GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO CONTRIBUTE TO THE MARKET SHARE
11.3
VACCINES
11.3.1
EXPANDING VACCINE PLATFORM COMPLEXITY AND STRICTER GLOBAL QUALITY EXPECTATIONS TO DRIVE MARKET GROWTH
11.4
CELLULAR & GENE THERAPY PRODUCTS
11.4.1
GROWING PRODUCT MANUFACTURING COMPLEXITY IS ACCELERATING DEMAND
11.5
BLOOD & BLOOD PRODUCTS
11.5.1
GROWING DEMAND FOR BLOOD PRODUCTS TO PROMOTE MARKET GROWTH
11.6
OTHER APPLICATIONS
12
BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
216
12.1
INTRODUCTION
12.2
MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING
12.2.1
EXPANDING ANTIBODY PIPELINES AND RISING BIOSIMILAR MANUFACTURING ARE DRIVING GROWTH
12.3
VACCINE SAFETY TESTING
12.3.1
EXPANSION OF VACCINE SAFETY TESTING DRIVEN BY ADVANCED PLATFORMS AND REGULATORY STRINGENCY
12.4
CELLULAR & GENE THERAPY SAFETY TESTING
12.4.1
EXPANDING ADVANCED THERAPY MANUFACTURING AND TIGHTER STERILITY REQUIREMENTS TO ACCELERATE DEMAND
12.5
BLOOD & BLOOD PRODUCT SAFETY TESTING
12.5.1
PLASMA PRODUCT SAFETY REQUIREMENTS AND NEW ASSAY APPROVALS TO DRIVE MARKET GROWTH
12.6
OTHER APPLICATIONS
13
BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
235
13.1
INTRODUCTION
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1
RISING ADOPTION OF SAFETY TESTING PRODUCTS BY BIOPHARMA MANUFACTURERS
13.3
CROS & CDMOS
13.3.1
RISING OUTSOURCING OF BIOLOGICS DEVELOPMENT AND MANUFACTURING ACCELERATES MARKET GROWTH
13.4
ACADEMIC & RESEARCH INSTITUTES
13.4.1
EXPANDING TRANSLATIONAL BIOLOGICS RESEARCH AND EARLY-STAGE PLATFORM DEVELOPMENT DRIVES MARKET GROWTH
13.5
OTHER END USERS
14
BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
250
14.1
INTRODUCTION
14.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.2.1
GROWING OUTSOURCING OF SAFETY TESTING SERVICES BY BIOPHARMA COMPANIES TO AID GROWTH
14.3
ACADEMIC & RESEARCH INSTITUTES
14.3.1
RISING TRANSLATIONAL RESEARCH IS DRIVING ADOPTION OF BIOLOGICS SAFETY TESTING SERVICES IN ACADEMIC INSTITUTES
14.4
OTHER END USERS
15
BIOLOGICS SAFETY TESTING MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 17 Countries | 287 Data Tables.
262
15.1
INTRODUCTION
15.2
NORTH AMERICA
15.2.1
US
15.2.1.1
LEADING BIOPHARMA INDUSTRY, FEDERAL FUNDING, MATURE ECOSYSTEM, AND BIOLOGICS DEVELOPMENT ACTIVITY TO PROPEL MARKET GROWTH
15.2.2
CANADA
15.2.2.1
INVESTMENTS FOR EXPANDING BIOMANUFACTURING CAPACITY TO PROPEL MARKET GROWTH
15.3
EUROPE
15.3.1
GERMANY
15.3.1.1
EXPANSION INITIATIVES BY KEY MARKET PLAYERS TO SUPPORT MARKET GROWTH
15.3.2
UK
15.3.2.1
EMPHASIS ON VACCINE MANUFACTURING AND BIOTECH R&D TO DRIVE MARKET
15.3.3
FRANCE
15.3.3.1
STRONG GOVERNMENT FUNDING DRIVING BIOLOGICS INNOVATION AND TESTING DEMAND
15.3.4
ITALY
15.3.4.1
MANUFACTURING INVESTMENT AND STRONG R&D INTENSITY SUPPORT MARKET GROWTH
15.3.5
SPAIN
15.3.5.1
GROWING EXPANSION OF BIOTECH COMPANIES AND INCREASING R&D EXPENDITURE TO DRIVE MARKET
15.3.6
REST OF EUROPE
15.4
ASIA PACIFIC
15.4.1
CHINA
15.4.1.1
RISING BIOLOGICS DEVELOPMENT DRIVING MARKET GROWTH
15.4.2
JAPAN
15.4.2.1
GOVERNMENT INITIATIVES AND EXPANSION OF BIOPHARMA COMPANIES TO BOOST MARKET
15.4.3
INDIA
15.4.3.1
EXPANDING BIOLOGICS CAPABILITIES AND RISING DEMAND FOR TARGETED ONCOLOGY THERAPIES DRIVE MARKET GROWTH
15.4.4
SOUTH KOREA
15.4.4.1
GROWING FOCUS ON ADVANCING BIOPROCESSING SECTOR TO DRIVE MARKET
15.4.5
AUSTRALIA
15.4.5.1
STRONG REGULATORY FRAMEWORK, CLINICAL INNOVATION, AND GLOBAL PARTNERSHIPS DRIVE MARKET GROWTH
15.4.6
REST OF ASIA PACIFIC
15.5
LATIN AMERICA
15.5.1
BRAZIL
15.5.1.1
EXPANDING BIOLOGICS MANUFACTURING INVESTMENT AND RISING CLINICAL DEVELOPMENT ACTIVITY ARE DRIVING MARKET GROWTH
15.5.2
MEXICO
15.5.2.1
INCREASING GOVERNMENT SUPPORT FOR BIOPHARMACEUTICAL PRODUCTION TO DRIVE MARKET
15.5.3
REST OF LATIN AMERICA
15.6
MIDDLE EAST
15.6.1
GCC COUNTRIES
15.6.1.1
SAUDI ARABIA
15.6.1.1.1
INCREASING HEALTHCARE EXPENDITURE AND RISING FOCUS OF KEY PLAYERS ON EXPANSION TO SUPPORT GROWTH
15.6.1.2
UNITED ARAB EMIRATES
15.6.1.2.1
DEVELOPING BIOPHARMA SECTOR TO DRIVE MARKET
15.6.1.3
REST OF GCC COUNTRIES
15.6.2
REST OF MIDDLE EAST
15.7
AFRICA
15.7.1
RISING AWARENESS AND COLLABORATIVE INITIATIVES TO DRIVE ADOPTION
16
COMPETITIVE LANDSCAPE
Uncover key player strategies and market dominance shaping the competitive landscape for 2025.
397
16.1
INTRODUCTION
16.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
16.3
REVENUE ANALYSIS
16.4
MARKET SHARE ANALYSIS
16.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
16.5.1
STARS
16.5.2
EMERGING LEADERS
16.5.3
PERVASIVE PLAYERS
16.5.4
PARTICIPANTS
16.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
16.5.5.1
COMPANY FOOTPRINT
16.5.5.2
REGION FOOTPRINT
16.5.5.3
OFFERING FOOTPRINT
16.5.5.4
TEST TYPE FOOTPRINT
16.5.5.5
APPLICATION FOOTPRINT OF COMPANIES
16.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
16.6.1
PROGRESSIVE COMPANIES
16.6.2
RESPONSIVE COMPANIES
16.6.3
DYNAMIC COMPANIES
16.6.4
STARTING BLOCKS
16.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
16.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
16.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
16.7
COMPANY VALUATION & FINANCIAL METRICS
16.8
BRAND/PRODUCT COMPARATIVE ANALYSIS
16.9
COMPETITIVE SCENARIO
16.9.1
PRODUCT LAUNCHES
16.9.2
DEALS
16.9.3
EXPANSIONS
17
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
420
17.1
MAJOR PALYER
17.1.1
THERMO FISHER SCIENTIFIC INC.
17.1.1.1
BUSINESS OVERVIEW
17.1.1.2
PRODUCTS/SERVICES/SOLUTIONS OFFERED
17.1.1.3
RECENT DEVELOPMENTS
17.1.1.3.1
SERVICE LAUNCHES
17.1.1.3.2
DEALS
17.1.1.3.3
EXPANSIONS
17.1.1.4
MNM VIEW
17.1.1.4.1
KEY STRENGTHS
17.1.1.4.2
STRATEGIC CHOICES
17.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
17.1.2
CHARLES RIVER LABORATORIES
17.1.3
LABORATORY CORPORATION OF AMERICA HOLDINGS
17.1.4
F. HOFFMANN-LA ROCHE LTD.
17.1.5
MERCK KGAA
17.1.6
SARTORIUS AG
17.1.7
LONZA
17.1.8
FUJIFILM CORPORATION
17.1.9
BIOMÉRIEUX
17.1.10
MARAVAI LIFESCIENCES
17.1.11
WUXI APPTEC
17.1.12
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA
17.1.13
SOTERA HEALTH
17.1.14
SAMSUNG BIOLOGICS
17.1.15
GENSCRIPT
17.1.16
AGILENT TECHNOLOGIES, INC.
17.1.17
SYNGENE INTERNATIONAL LIMITED
17.1.18
EUROFINS SCIENTIFIC
17.1.19
BIO-RAD LABORATORIES, INC.
17.1.20
QIAGEN
17.2
OTHER PLAYERS
17.2.1
PROMEGA CORPORATION
17.2.2
CATALENT, INC.
17.2.3
ASSOCIATES OF CAPE COD, INC.
17.2.4
CLEAN BIOLOGICS
17.2.5
PATHOQUEST
17.2.6
PACIFIC BIOLABS
17.2.7
ARL BIO PHARMA, INC.
17.2.8
FRONTAGE LABS
17.2.9
CREATIVE BIOGENE
17.2.10
ADVAXIA BIOLOGICS
18
RESEARCH METHODOLOGY
506
18.1
RESEARCH DATA
18.1.1
SECONDARY DATA
18.1.2
PRIMARY DATA
18.2
MARKET ESTIMATION METHODOLOGY
18.2.1
MARKET SIZE ESTIMATION
18.2.2
INSIGHTS OF PRIMARY EXPERTS
18.2.3
TOP-DOWN APPROACH
18.3
MARKET GROWTH RATE PROJECTIONS
18.4
MARKET BREAKDOWN AND DATA TRIANGULATION
18.5
RESEARCH ASSUMPTIONS
18.6
RESEARCH LIMITATIONS
18.7
RISK ANALYSIS
19
APPENDIX
518
19.1
DISCUSSION GUIDE
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
19.4
RELATED REPORTS
19.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
BIOLOGICS SAFETY TESTING MARKET: IMPACT ANALYSIS
TABLE 2
BIOLOGICS SAFETY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3
BIOLOGICS SAFETY TESTING MARKET: ROLE IN ECOSYSTEM
TABLE 4
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
TABLE 5
INDICATIVE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2025
TABLE 6
BIOLOGICS SAFETY TESTING MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 7
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 8
APPLICATIONS OF PCR IN BIOLOGICS SAFETY TESTING
TABLE 9
INDICATIVE LIST OF PATENTS IN BIOLOGICS SAFETY TESTING MARKET, 2025
TABLE 10
CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET
TABLE 11
CLIENT’S READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET
TABLE 12
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
COUNTRY-WISE REGULATORY SCENARIO FOR BIOLOGICS SAFETY TESTING MANUFACTURERS
TABLE 17
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
TABLE 18
KEY BUYING CRITERIA, BY END USER
TABLE 19
BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 20
BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 21
BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 22
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 23
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 24
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 27
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28
VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 29
NORTH AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30
EUROPE: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31
ASIA PACIFIC: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32
LATIN AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33
MIDDLE EAST: VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 34
GCC COUNTRIES: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35
STERILITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 36
NORTH AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
EUROPE: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38
ASIA PACIFIC: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39
LATIN AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40
MIDDLE EAST: STERILITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 41
GCC COUNTRIES: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43
NORTH AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44
EUROPE: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
ASIA PACIFIC: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46
LATIN AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47
MIDDLE EAST: MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48
GCC COUNTRIES: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50
NORTH AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
EUROPE: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52
ASIA PACIFIC: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53
LATIN AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
MIDDLE EAST: ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55
GCC COUNTRIES: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57
NORTH AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58
EUROPE: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
ASIA PACIFIC: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60
LATIN AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61
MIDDLE EAST: BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62
GCC COUNTRIES: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63
OTHER BST SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 64
NORTH AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
EUROPE: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
ASIA PACIFIC: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67
LATIN AMERICA: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68
MIDDLE EAST: OTHER BST SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69
GCC COUNTRIES: OTHER BST SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 71
BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 72
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 79
BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 80
NORTH AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
EUROPE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
ASIA PACIFIC: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83
LATIN AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84
MIDDLE EAST: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 85
GCC COUNTRIES: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
DETECTION KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 87
NORTH AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88
EUROPE: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89
ASIA PACIFIC: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90
LATIN AMERICA: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91
MIDDLE EAST: DETECTION KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 92
GCC COUNTRIES: DETECTION KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 94
NORTH AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95
EUROPE: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96
ASIA PACIFIC: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97
LATIN AMERICA: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98
MIDDLE EAST: ENDOTOXIN TESTING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 99
GCC COUNTRIES: ENDOTOXIN TESTING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 101
NORTH AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
EUROPE: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103
ASIA PACIFIC: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104
LATIN AMERICA: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105
MIDDLE EAST: STERILITY TESTING MEDIA & KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 106
GCC COUNTRIES: STERILITY TESTING MEDIA & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107
BIOBURDEN ENUMERATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 108
NORTH AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109
EUROPE: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110
ASIA PACIFIC: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111
LATIN AMERICA: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112
MIDDLE EAST: BIOBURDEN ENUMERATION MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113
GCC COUNTRIES: BIOBURDEN ENUMERATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 115
NORTH AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116
EUROPE: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117
ASIA PACIFIC: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118
LATIN AMERICA: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119
MIDDLE EAST: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120
GCC COUNTRIES: OTHER BST ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121
BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122
BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 123
NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124
EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125
ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126
LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127
MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 128
GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129
DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 130
NORTH AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131
EUROPE: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132
ASIA PACIFIC: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133
LATIN AMERICA: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134
MIDDLE EAST: DETECTION & IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 135
GCC COUNTRIES: DETECTION & IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136
SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 137
NORTH AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138
EUROPE: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139
ASIA PACIFIC: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140
LATIN AMERICA: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141
MIDDLE EAST: SEQUENCING INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 142
GCC COUNTRIES: SEQUENCING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143
AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 144
NORTH AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145
EUROPE: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146
ASIA PACIFIC: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147
LATIN AMERICA: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148
MIDDLE EAST: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 149
GCC COUNTRIES: AUTOMATED STERILITY TESTING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150
OTHER BST INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 151
NORTH AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152
EUROPE: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153
ASIA PACIFIC: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154
LATIN AMERICA: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155
MIDDLE EAST: OTHER BST INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 156
GCC COUNTRIES: OTHER BST INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157
BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 158
VIRUS SAFETY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159
NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160
EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161
ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162
LATIN AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163
MIDDLE EAST: VIRUS SAFETY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 164
GCC COUNTRIES: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165
STERILITY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 166
NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167
EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168
ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169
LATIN AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170
MIDDLE EAST: STERILITY TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 171
GCC COUNTRIES: STERILITY TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172
ENDOTOXIN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 173
NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174
EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175
ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
LATIN AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177
MIDDLE EAST: ENDOTOXIN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 178
GCC COUNTRIES: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179
MYCOPLASMA TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 180
NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181
EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182
ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183
LATIN AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184
MIDDLE EAST: MYCOPLASMA TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 185
GCC COUNTRIES: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186
BIOBURDEN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 187
NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188
EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189
ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190
LATIN AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191
MIDDLE EAST: BIOBURDEN TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192
GCC COUNTRIES: BIOBURDEN TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193
RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 194
NORTH AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195
EUROPE: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196
ASIA PACIFIC: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197
LATIN AMERICA: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198
MIDDLE EAST: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 199
GCC COUNTRIES: RESIDUAL HCP & DNA DETECTION TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200
OTHER TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 201
NORTH AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202
EUROPE: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203
ASIA PACIFIC: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204
LATIN AMERICA: OTHER TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205
MIDDLE EAST: OTHER TESTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 206
GCC COUNTRIES: OTHER BST TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207
BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 208
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024–2031 (USD MILLION)
TABLE 209
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY REGION, 2024–2031 (USD MILLION)
TABLE 214
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 216
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY REGION, 2024–2031 (USD MILLION)
TABLE 221
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR VACCINES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 223
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 228
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CELLULAR & GENE THERAPY PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 230
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 235
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR BLOOD & BLOOD PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 237
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 242
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243
BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 244
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 245
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 250
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 252
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 257
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR VACCINE SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 259
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 264
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR CELLULAR & GENE THERAPY SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 266
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 268
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 271
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR BLOOD & BLOOD PRODUCT SAFETY TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 272
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 273
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 274
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 275
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 277
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 278
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 279
BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 280
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 281
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 282
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 284
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 285
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 286
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 287
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 288
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 289
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 290
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 291
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 292
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION)
TABLE 293
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 294
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 295
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 296
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 297
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 299
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 300
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 301
BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 302
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 303
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 304
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 305
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 306
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 307
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 308
BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 309
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 310
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 311
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 312
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 313
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 314
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 315
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 316
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 317
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 318
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 319
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 320
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 321
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 322
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 323
BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 324
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 325
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 326
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 327
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 328
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 329
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 330
BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 331
NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 332
NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 333
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 334
NORTH AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 335
NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 336
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 337
NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 338
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 339
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 340
NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 341
NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 342
US: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 343
US: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 344
US: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 345
US: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 346
US: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 347
US: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 348
US: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 349
US: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 350
US: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 351
US: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 352
CANADA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 353
CANADA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 354
CANADA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 355
CANADA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 356
CANADA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 357
CANADA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 358
CANADA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 359
CANADA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 360
CANADA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 361
CANADA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 362
EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 363
EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 364
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 365
EUROPE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 366
EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 367
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 368
EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 369
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 370
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 371
EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 372
EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 373
GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 374
GERMANY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 375
GERMANY: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 376
GERMANY: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 377
GERMANY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 378
GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 379
GERMANY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 380
GERMANY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 381
GERMANY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 382
GERMANY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 383
UK: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 384
UK: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 385
UK: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 386
UK: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 387
UK: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 388
UK: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 389
UK: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 390
UK: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 391
UK: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 392
UK: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 393
FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 394
FRANCE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 395
FRANCE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 396
FRANCE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 397
FRANCE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 398
FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 399
FRANCE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 400
FRANCE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 401
FRANCE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 402
FRANCE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 403
ITALY: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 404
ITALY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 405
ITALY: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 406
ITALY: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 407
ITALY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 408
ITALY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 409
ITALY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 410
ITALY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 411
ITALY: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 412
ITALY: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 413
SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 414
SPAIN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 415
SPAIN: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 416
SPAIN: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 417
SPAIN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 418
SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 419
SPAIN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 420
SPAIN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 421
SPAIN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 422
SPAIN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 423
REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 424
REST OF EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 425
REST OF EUROPE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 426
REST OF EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 427
REST OF EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 428
REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 429
REST OF EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 430
REST OF EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 431
REST OF EUROPE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 432
REST OF EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 433
ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 434
ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 435
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 436
ASIA PACIFIC: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 437
ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 438
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 439
ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 440
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 441
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 442
ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 443
ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 444
CHINA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 445
CHINA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 446
CHINA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 447
CHINA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 448
CHINA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 449
CHINA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 450
CHINA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 451
CHINA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 452
CHINA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 453
CHINA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 454
JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 455
JAPAN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 456
JAPAN: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 457
JAPAN: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 458
JAPAN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 459
JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 460
JAPAN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 461
JAPAN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 462
JAPAN: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 463
JAPAN: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 464
INDIA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 465
INDIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 466
INDIA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 467
INDIA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 468
INDIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 469
INDIA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 470
INDIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 471
INDIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 472
INDIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 473
INDIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 474
SOUTH KOREA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 475
SOUTH KOREA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 476
SOUTH KOREA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 477
SOUTH KOREA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 478
SOUTH KOREA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 479
SOUTH KOREA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 480
SOUTH KOREA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 481
SOUTH KOREA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 482
SOUTH KOREA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 483
SOUTH KOREA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 484
AUSTRALIA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 485
AUSTRALIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 486
AUSTRALIA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 487
AUSTRALIA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 488
AUSTRALIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 489
AUSTRALIA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 490
AUSTRALIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 491
AUSTRALIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 492
AUSTRALIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 493
AUSTRALIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 494
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 495
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 496
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 497
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 498
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 499
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 500
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 501
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 502
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 503
REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 504
LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 505
LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 506
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 507
LATIN AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 508
LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 509
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 510
LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 511
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 512
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 513
LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 514
LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 515
BRAZIL: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 516
BRAZIL: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 517
BRAZIL: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 518
BRAZIL: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 519
BRAZIL: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 520
BRAZIL: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 521
BRAZIL: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 522
BRAZIL: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 523
BRAZIL: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 524
BRAZIL: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 525
MEXICO: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 526
MEXICO: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 527
MEXICO: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 528
MEXICO: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 529
MEXICO: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 530
MEXICO: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 531
MEXICO: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 532
MEXICO: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 533
MEXICO: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 534
MEXICO: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 535
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 536
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 537
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 538
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 539
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 540
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 541
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 542
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 543
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 544
REST OF LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 545
MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 546
MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 547
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 548
MIDDLE EAST: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 549
MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 550
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 551
MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 552
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 553
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 554
MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 555
MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 556
GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 557
GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 558
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 559
GCC COUNTRIES: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 560
GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 561
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 562
GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 563
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 564
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 565
GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 566
GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 567
SAUDI ARABIA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 568
SAUDI ARABIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 569
SAUDI ARABIA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 570
SAUDI ARABIA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 571
SAUDI ARABIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 572
SAUDI ARABIA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 573
SAUDI ARABIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 574
SAUDI ARABIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 575
SAUDI ARABIA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 576
SAUDI ARABIA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 577
UAE: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 578
UAE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 579
UAE: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 580
UAE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 581
UAE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 582
UAE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 583
UAE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 584
UAE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 585
UAE: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 586
UAE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 587
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 588
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 589
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 590
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 591
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 592
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 593
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 594
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 595
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 596
REST OF GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 597
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 598
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 599
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 600
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 601
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 602
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 603
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 604
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 605
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 606
REST OF MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 607
AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 608
AFRICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 609
AFRICA: BIOLOGICS SAFETY TESTING ASSAYS, KITS, AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 610
AFRICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 611
AFRICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 612
AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 613
AFRICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 614
AFRICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 615
AFRICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 616
AFRICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 617
STRATEGIES ADOPTED BY KEY PLAYERS IN BIOLOGICS SAFETY TESTING MARKET, 2023−2026
TABLE 618
BIOLOGICS SAFETY TESTING MARKET: DEGREE OF COMPETITION
TABLE 619
BIOLOGICS SAFETY TESTING MARKET: REGION FOOTPRINT
TABLE 620
BIOLOGICS SAFETY TESTING MARKET: OFFERING FOOTPRINT
TABLE 621
BIOLOGICS SAFETY TESTING MARKET: TEST TYPE FOOTPRINT
TABLE 622
BIOLOGICS SAFETY TESTING MARKET: OFFERINGS APPLICATION FOOTPRINT
TABLE 623
BIOLOGICS SAFETY TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 624
BIOLOGICS SAFETY TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 625
BIOLOGICS SAFETY TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2023 TO MARCH 2026
TABLE 626
BIOLOGICS SAFETY TESTING MARKET: DEALS, JANUARY 2023 TO APRIL 2026
TABLE 627
BIOLOGICS SAFETY TESTING MARKET: EXPANSIONS, JANUARY 2023 TO APRIL 2026
TABLE 628
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 629
THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 630
THERMO FISHER SCIENTIFIC INC: SERVICE LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 631
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 632
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 633
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 634
CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 635
CHARLES RIVER LABORATORIES: PRODUCT AND SERVICE LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 636
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–APRIL 2026
TABLE 637
LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
TABLE 638
LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 639
LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2023–APRIL 2026
TABLE 640
LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 641
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 642
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 643
F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 644
F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 645
MERCK KGAA: COMPANY OVERVIEW
TABLE 646
MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 647
MERCK KGAA: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 648
SARTORIUS AG: COMPANY OVERVIEW
TABLE 649
SARTORIUS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 650
SARTORIUS AG: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 651
LONZA: COMPANY OVERVIEW
TABLE 652
LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 653
LONZA: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 654
LONZA: DEALS, JANUARY 2023–APRIL 2026
TABLE 655
FUJIFILM CORPORATION: COMPANY OVERVIEW
TABLE 656
FUJIFILM CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 657
FUJIFILM CORPORATION: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 658
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 659
BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 660
BIOMÉRIEUX: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 661
BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026
TABLE 662
MARAVAI LIFESCIENCES: COMPANY OVERVIEW
TABLE 663
MARAVAI LIFESCIENCES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 664
MARAVAI LIFESCIENCES: DEALS, JANUARY 2023–APRIL 2026
TABLE 665
WUXI APPTEC: COMPANY OVERVIEW
TABLE 666
WUXI APPTEC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 667
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW
TABLE 668
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: PRODUCTS/ SERVICES/SOLUTIONS OFFERED
TABLE 669
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: SERVICE LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 670
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 671
SOTERA HEALTH: COMPANY OVERVIEW
TABLE 672
SOTERA HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 673
SOTERA HEALTH: SERVICE LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 674
SOTERA HEALTH: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 675
SAMSUNG BIOLOGICS: COMPANY OVERVIEW
TABLE 676
SAMSUNG BIOLOGICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 677
SAMSUNG BIOLOGICS: DEALS, JANUARY 2023–APRIL 2026
TABLE 678
SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 679
GENSCRIPT: COMPANY OVERVIEW
TABLE 680
GENSCRIPT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 681
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 682
AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 683
SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
TABLE 684
SYNGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 685
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 686
EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 687
EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 688
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–APRIL 2026
TABLE 689
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 690
BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 691
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 692
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–APRIL 2026
TABLE 693
QIAGEN: COMPANY OVERVIEW
TABLE 694
QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 695
QIAGEN: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026
TABLE 696
PROMEGA CORPORATION: COMPANY OVERVIEW
TABLE 697
CATALENT, INC.: COMPANY OVERVIEW
TABLE 698
ASSOCIATES OF CAPE COD, INC.: COMPANY OVERVIEW
TABLE 699
CLEAN BIOLOGICS: COMPANY OVERVIEW
TABLE 700
PATHOQUEST: COMPANY OVERVIEW
TABLE 701
PACIFIC BIOLABS: COMPANY OVERVIEW
TABLE 702
ARL BIO PHARMA, INC.: COMPANY OVERVIEW
TABLE 703
FRONTAGE LABS: COMPANY OVERVIEW
TABLE 704
CREATIVE BIOGENE: COMPANY OVERVIEW
TABLE 705
ADVAXIA BIOLOGICS: COMPANY OVERVIEW
TABLE 706
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
LIST OF FIGURES
FIGURE 1
MARKET SCENARIO
FIGURE 2
GLOBAL BIOLOGICS SAFETY TESTING MARKET, 2024–2031
FIGURE 3
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOLOGICS SAFETY TESTING MARKET, 2023–2026
FIGURE 4
DISRUPTIONS INFLUENCING GROWTH OF BIOLOGICS SAFETY TESTING MARKET
FIGURE 5
HIGH-GROWTH SEGMENTS IN BIOLOGICS SAFETY TESTING MARKET, 2026–2031
FIGURE 6
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOLOGICS SAFETY TESTING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 7
GROWING BIOLOGICS AND BIOSIMILARS PIPELINE TO DRIVE GROWTH IN BIOLOGICS SAFETY TESTING MARKET
FIGURE 8
SERVICES SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE, BY OFFERING, IN 2025
FIGURE 9
CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 10
BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11
BIOLOGICS SAFETY TESTING MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 12
BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS
FIGURE 13
BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS
FIGURE 14
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025 (USD)
FIGURE 15
INDICATIVE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2025
FIGURE 16
BIOLOGICS SAFETY TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 17
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
FIGURE 18
TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015–2025
FIGURE 19
IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET
FIGURE 20
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
FIGURE 21
KEY BUYING CRITERIA, BY END USER
FIGURE 22
NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
FIGURE 23
ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
FIGURE 24
REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
FIGURE 25
MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
FIGURE 26
BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 27
BIOLOGICS SAFETY TESTING MARKET: COMPANY FOOTPRINT
FIGURE 28
BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 29
EV/EBITDA OF KEY VENDORS
FIGURE 30
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 31
BIOLOGICS SAFETY TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 32
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 33
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025)
FIGURE 34
LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2025)
FIGURE 35
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 36
MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 37
SARTORIUS AG: COMPANY SNAPSHOT (2025)
FIGURE 38
LONZA: COMPANY SNAPSHOT (2025)
FIGURE 39
FUJIFILM CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 40
BIOMÉRIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41
MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
FIGURE 42
WUXI APPTEC: COMPANY SNAPSHOT
FIGURE 43
SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2025)
FIGURE 44
SOTERA HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 45
SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2025)
FIGURE 46
GENSCRIPT: COMPANY SNAPSHOT (2025)
FIGURE 47
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 48
SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 49
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 50
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 51
QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 52
RESEARCH DESIGN
FIGURE 53
BIOLOGICS SAFETY TESTING MARKET: BREAKDOWN OF PRIMARIES
FIGURE 54
BIOLOGICS SAFETY TESTING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 55
MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
FIGURE 56
REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2025)
FIGURE 57
MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 58
MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 59
BIOLOGICS SAFETY TESTING MARKET CAGR PROJECTIONS
FIGURE 60
DATA TRIANGULATION METHODOLOGY
Methodology
This study involved four major activities in estimating the current size of the biologics safety testing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), News Articles, Press Releases. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global biologics safety testing market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biologics safety testing market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The biological safety testing market comprises the products and services used to assess the safety, purity, potency, and quality of biologically derived products across their development, manufacturing, and release stages.
Key Stakeholders
- Biologics safety testing products and services companies
- National and regional research boards and organizations
- Research & development companies
- Clinical research organizations (CROs)
- Biotechnology companies
- Research laboratories & academic institutes
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the biologics safety testing market by offering, test type, product application, service application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biologics safety testing market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biologics safety testing market, by country
- Further breakdown of the Rest of Asia Pacific biologics safety testing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Biologics Safety Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Biologics Safety Testing Market
Still Researching the
Biologics Safety Testing Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
Explore Biologics Safety Testing Intelligence
Powered by 17 years of MarketsandMarkets intelligence
Biocompatibility
Nov, 2020
Fantastic piece of content. Thank you for sharing this..